Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Gadolinium-based contrast agent (GBCA) Clear all

Conditions: Renal Insufficiency
Interventions: Not listed
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: Not listed
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Nephrogenic Systemic Fibrosis, Nephrogenic Fibrosing Dermopathy
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Indian Wells, California • Orange, California • Miami, Florida + 5 more

Conditions: Contrast Enhancement in Magnetic Resonance Imaging
Interventions: BAY1747846; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Knoxville, Tennessee

Conditions: Central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania

Conditions: Liver Lesion
Interventions: Radiology, Gadopiclenol; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 89 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer of the Rectum, Neoplasms, Rectal, Rectal Cancer, Rectal Tumors, Rectal Adenocarcinoma
Interventions: Diagnostic Biopsy and Surgical Procedure, Intravoxel incoherent motion MRI (IVIM), Dynamic Contrast Enhanced MRI (DCE-MRI), RNA gene expression analysis; Procedure · Genetic
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions: PET Tracer, MRI Tracer, 3T PET/MRI; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer Disease
Interventions: GRASP Dynamic Contrast-Enhanced (DCE) MRI, 3T Brain Scan, Gadolinium-based Contrast Agent (GBCA) for MRI; Device · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 20 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Covid19, Cardiac Disease, Cardiac Arrhythmia, Myocarditis, Left Ventricular Dysfunction
Interventions: Transthoracic echocardiogram (TTE), Cardiovascular Magnetic Resonance (CMR) Imaging; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocardial Fibrosis
Interventions: Elucirem (Gadopiclenol); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Magnetic Resonance Imaging Contrast Agents
Interventions: Magnevist, Dotarem, Gadovist; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 21 Years
Enrollment: 500 participants
Timeline: 1990 – 2019
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Focus: Long-term Retention of Gadolinium-based Contrast Agent
Interventions: Gadolinium analysis in bone and tissue samples; Procedure
Lead sponsor: Navitas Life Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lobular Breast Carcinoma
Interventions: 18Fluoroestradiol (18F-FES), MRI, Gadolinium-based contrast agent (GBCA); Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
Interventions: Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lupus Nephritis
Interventions: MRI; Procedure
Lead sponsor: RILITE Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • New York, New York • Columbus, Ohio + 2 more

Conditions: Motor Function, Cognitive Function, Contrast Media
Interventions: Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol; Procedure · Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 16
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more

Conditions: Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions
Interventions: Portable MRI (pMRI), Gadolinium-Based Contrast Agent (GBCA); Device · Drug
Lead sponsor: Hyperfine; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Altamonte Springs, Florida • Boston, Massachusetts • Amherst, New York + 3 more

Conditions: Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
Interventions: 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, MRI-Based Angiogram; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Congenital Heart Disease
Interventions: Gadopiclenol, Gadobenate dimeglumine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: CAD
Interventions: MRI scan - obj 1, MRI scans - obj 2, MRI scans - obj 3, MRI scans - obj 4; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 2,950 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Kidney Disease, Renal Insufficiency
Interventions: Omniscan; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Princeton, New Jersey

Search by objective public record fields.

Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)

Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Gadopiclenol vs Gadoxetate MRI for Liver Lesions

Immunoscore in Rectal Cancer

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry

High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

Long-Term Retention of Gadolinium in Bone

FES PET/MRI for Occult Disease in Lobular Breast Cancer

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

Dynamic Imaging of Variation in Lupus Nephritis

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics

Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)